Davina Daudu

Dr. Davina Daudu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GHGeorgia KB Halkett
Georgia KB Halkett
MBMelissa N. Berg
Melissa N. Berg
DDDavina Daudu
Davina Daudu
HDHaryana Dhillon
Haryana Dhillon
EKEng-Siew Koh
Eng-Siew Koh
ANAnna K. Nowak
Anna K. Nowak
Purpose: This study aimed to: determine the supportive care available for Australian patients with High Grade Glioma (HGG) and their carers; identify service gaps; and inform changes needed to implement guidelines and Optimal Care Pathways. Methods: This cross-sectional online survey recruited multidisciplinary health professionals (HPs) who were members of the Cooperative Trials Group for Neuro-Oncology involved in management of patients diagnosed with HGG in Australian hospitals. Descriptive statistics were calculated. Fisher's exact test was used to explore differences between groups. Results: 42 complete responses were received. A majority of MDT meetings were attended by a: neurosurgeon, radiation oncologist, medical oncologist, radiologist, and care coordinator. Less than 10% reported attendance by a palliative care nurse; physiotherapist; neuropsychologist; or speech therapist. Most could access referral pathways to a cancer care coordinator (76%), neuropsychologist (78%), radiation oncology nurse (77%), or psycho-oncologist (73%), palliative care (93–100%) and mental health professionals (60–85%). However, few routinely referred to an exercise physiologist (10%), rehabilitation physician (22%), dietitian (22%) or speech therapist (28%). Similarly, routine referrals to specialist mental health services were not standard practice. Nearly all HPs (94%) reported HGG patients were advised to present to their GP for pre-existing conditions/comorbidities; however, most HPs took responsibility (≤ 36% referred to GP) for social issues, mental health, symptoms, cancer complications, and treatment side-effects. Conclusions: While certain services are accessible to HGG patients nationally, improvements are needed. Psychosocial support, specialist allied health, and primary care providers are not yet routinely integrated into the care of HGG patients and their carers despite these services being considered essential in clinical practice guidelines and optimal care pathways.

28 February 2024 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
NMN. Moody
N. Moody
AWA. Walter
A. Walter
DDDavina Daudu
Davina Daudu
CWCarl-Magnus Wahlgren
Carl-Magnus Wahlgren
VJVincent Jongkind
Vincent Jongkind
Objective: Extremity vascular trauma in children can result in significant fi cant morbidity and mortality. Most published studies have focused on supracondylar humeral fracture related injuries, with little focus on other injuries. This scoping review describes the current state of knowledge on paediatric vascular injuries in the upper and lower limbs, excluding injuries related to supracondylar humeral fractures. Methods: MEDLINE, PubMed, Web of Science, and Cochrane databases were searched for relevant studies evaluating the epidemiology, diagnosis, management, and outcomes of upper and lower limb vascular trauma in those aged under 18 years. Studies related to supracondylar humeral fractures were excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews was used. Results: A total of 39 studies was included, all of which were retrospective, and 74% of which were based in North America or Europe. Extremity vascular trauma was reported to cause 0.6- 4.4% of all paediatric trauma admissions, with penetrating mechanisms and upper limb injuries being the most common. Operative intervention was reported in 80- 100% of children in the included studies. Primary repair was the most commonly reported operative intervention, followed by interposition graft and bypass graft. Synthetic graft use was less commonly reported (incidence range 0.5- 33%). Lower limb fasciotomies and amputations were not commonly reported (incidence range 0- 23% and 0- 13%, respectively). The mortality rate appeared low, with 23 studies reporting no deaths (incidence range 0- 4%). Complications were reported inconsistently, with no uniform outcome or follow up measures used. Conclusion: The incidence of extremity vascular trauma appears low in children, with penetrating mechanisms and upper extremity injuries appearing to dominate. Most studies are from high income countries, with probable selection bias towards those treated by operative intervention. Prospective studies are required focusing on patterns of injury, rates of operative and endovascular intervention, and long term outcomes.

26 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
NSNelson Encarnación Encarnacion S
Nelson Encarnación Encarnacion S
ALAlexandra Lansky
Alexandra Lansky
JGJon C. George
Jon C. George
Background/Objectives: Severe arterial calcification remains a major challenge during femoropopliteal endovascular intervention, limiting luminal gain and increasing the risk of vessel-wall injury, restenosis, and bailout stenting. Pulsatile intravascular lithotripsy (PIVL) is a novel calcium-modification technology that converts pneumatic pulses into short-duration hydraulic pressure waves delivered through a non-compliant balloon. POWER PAD I evaluated the first-in-human feasibility, safety, and procedural performance of PIVL in calcified femoropopliteal arterial disease. Methods: POWER PAD I was a prospective, single-arm, two-center feasibility study. Adults with Rutherford category 2–4 symptomatic peripheral arterial disease and moderately or severely calcified superficial femoral or popliteal lesions were treated with PIVL, followed by adjunctive therapy when clinically indicated. Angiographic and duplex ultrasound outcomes were assessed by an independent core laboratory, and adverse events were adjudicated by an independent clinical events committee. Results: Nine patients underwent treatment of 20 lesions. Mean age was 76.2 ± 12.6 years, 19 lesions were severely calcified, and five lesions were chronic total occlusions. Patient-level device and procedural success were each achieved in 8 of 9 patients; technical success was achieved in all patients. Mean diameter stenosis decreased from 76.5 ± 18.0% before treatment to 28.1 ± 6.9% after PIVL-containing lesion preparation and before adjunctive drug-coated-balloon angioplasty, and to 20.6 ± 5.8% after adjunctive therapy. Mean minimal luminal diameter increased from 1.3 ± 1.0 mm to 3.8 ± 0.5 mm after PIVL-containing lesion preparation and to 4.3 ± 0.6 mm at final angiography. No perforation, distal embolization, thrombus, abrupt closure, no-reflow, bailout stenting, or grade D or higher dissection occurred. Freedom from clinically driven target-lesion revascularization was 100% at 30 days and 6 months. Conclusions: PIVL-containing lesion preparation was feasible in heavily calcified superficial femoral and popliteal lesions and was associated with substantial acute luminal gain before adjunctive DCB therapy and no severe angiographic complications. Favorable 6-month clinical and patency outcomes were observed after the combined treatment strategy of PIVL vessel preparation and adjunctive DCB therapy; therefore, longer-term outcomes cannot be attributed to PIVL alone. Larger controlled studies are warranted.

16 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
IDIsabel Dwyer
Isabel Dwyer
DMDaniela Liezel Mwipatayi
Daniela Liezel Mwipatayi
JWJacqueline Wong
Jacqueline Wong
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background/Objectives: Drug-coated balloons (DCBs) provide local antiproliferative therapy during endovascular revascularization without leaving a permanent vascular scaffold. Sirolimus is an attractive cytostatic antiproliferative agent, although its relatively low lipophilicity creates challenges for rapid arterial uptake and sustained tissue residence following balloon delivery. The BRight DCB is a novel peripheral DCB coated with BIOtorcin™ (CRC-015), a highly lipophilic synthetic derivative of sirolimus. The BRight PK study primarily evaluated the systemic pharmacokinetics of BIOtorcin™ and its metabolite sirolimus following treatment of femoropopliteal disease and secondarily assessed procedural performance, safety, patency, and functional outcomes over 12 months. Methods: BRight PK was a prospective, single-center, non-randomized pharmacokinetic study involving six adults with symptomatic peripheral artery disease (PAD; Rutherford–Becker category 2–4) caused by de novo superficial femoral and/or proximal popliteal artery disease. Following mandatory predilatation, lesions were treated with one or two BRight DCBs. Whole-blood BIOtorcin™ and sirolimus concentrations were measured before treatment and serially from 5 min to 24 h after removal of the final DCB. Non-compartmental pharmacokinetic analysis was performed. Angiography and duplex ultrasound were independently assessed by a core laboratory, and endpoint-related clinical events were independently adjudicated. Results: All six participants completed 12-month follow-up. Mean age was 70.8 ± 7.4 years, and four (66.7%) were male. Seven BRight DCBs treated six lesions. Mean core-laboratory lesion length was 140.85 ± 136.23 mm, and baseline diameter stenosis was 78.50 ± 23.39%. Mean BIOtorcin™ exposure was 3976.8 ± 1665.7 µg (0.051 ± 0.0188 mg/kg). BIOtorcin™ Cmax was 23.60 ± 9.88 ng/mL at 5 min, terminal half-life was 21.87 ± 10.17 h, AUC0–t was 28.30 ± 12.19 h·ng/mL, and AUC0–∞ was 47.47 ± 18.27 h·ng/mL. Sirolimus Cmax was 0.692 ± 0.462 ng/mL at 24 h, when concentrations remained on the ascending portion of the concentration–time curve, indicating that the 24 h sampling window captured only early systemic sirolimus exposure rather than a complete pharmacokinetic profile. Device success was 100% (7/7); core-laboratory technical and procedural success were each 66.7% (4/6). No deaths, major or minor amputations, clinically driven target lesion revascularizations (cd-TLR), or clinically driven target vessel revascularizations (cd-TVRs) occurred. Visit-based 12-month primary patency was 83.3% (5/6); the single binary restenosis was detected at day 391, resulting in Kaplan–Meier primary patency of 100% at calendar day 365. The mean overall Walking Impairment Questionnaire (WIQ) score increased from 21.87 ± 19.16 at baseline to 62.28 ± 38.78 at 12 months. Conclusions: BIOtorcin™ demonstrated rapid systemic appearance following BRight DCB treatment, followed by a progressive decline in circulating parent drug concentrations and low systemic exposure to its metabolite, sirolimus. These pharmacokinetic findings, together with successful device delivery and the absence of major safety concerns over 12 months, demonstrate procedural feasibility and support continued clinical evaluation of the BRight DCB. Given the pharmacokinetic study design and small sample size (n = 6), the 12-month clinical, functional, and patency findings are exploratory and hypothesis-generating and should not be interpreted as evidence of clinical efficacy.

19 September 2024 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
NMN. Moody
N. Moody
AWA. Walter
A. Walter
DDDavina Daudu
Davina Daudu
CWC.-M. Wahlgren
C.-M. Wahlgren
VJV. Jongkind
V. Jongkind

Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
JDJames Evan Dodd
James Evan Dodd
MMMariah Theresa Mwipatayi
Mariah Theresa Mwipatayi
MSMarkus P SCHLAICH
Markus P SCHLAICH
Background: Restenosis and occlusion remain important after aortoiliac stenting, and device choice does not fully explain late patency loss. Lipoprotein(a) [Lp(a)] is implicated in atherosclerotic progression and residual vascular risk. Objective: To determine whether baseline Lp(a) is associated with long-term restenosis or occlusion after aortoiliac stenting. Methods: This post hoc biomarker analysis of COBEST included 125 patients and 168 treated iliac arteries randomised to the Advanta V12 covered stent (Atrium Medical Corporation, Hudson, NH, USA) or bare-metal stents for symptomatic aortoiliac occlusive disease. The primary outcome was loss of primary patency, defined as restenosis or occlusion during 5-year follow-up. Cox proportional hazards modelling and cumulative failure curves were the main analyses. Results: In the Lp(a)-adjusted Cox model, covered stent use was associated with a lower hazard of restenosis or occlusion (HR, 0.55; 95% CI, 0.31–0.97; p = 0.039), whereas each 1 mg/dL higher Lp(a) concentration was associated with a higher hazard (HR, 1.08; 95% CI, 1.06–1.10; p < 0.001; equivalent to HR, 2.16; 95% CI, 1.79–2.59 per 10 mg/dL increase). In the biomarker-adjusted model, each 1 mg/dL higher Lp(a) concentration (HR, 1.05; 95% CI, 1.02–1.08; p < 0.001; HR, 1.63; 95% CI, 1.22–2.16 per 10 mg/dL increase) and each 1 mmol/L higher triglyceride concentration (HR, 1.89; 95% CI, 1.34–2.68; p < 0.001) remained associated with restenosis or occlusion. Conclusions: Elevated Lp(a) and, to a lesser extent, triglycerides were independently associated with long-term aortoiliac stent failure after adjustment for stent type.